Voriconazole: Difference between revisions
ClaireLewis (talk | contribs) (Created page with "==Administration== *Type: Antifungal (Candida, mycoses, Aspergillosis) *Dosage Forms: *Routes of Administration: IV, PO *Common Trade Names: ==Adult Dosing== *20...") |
Elcatracho (talk | contribs) |
||
| (4 intermediate revisions by 4 users not shown) | |||
| Line 3: | Line 3: | ||
*Dosage Forms: | *Dosage Forms: | ||
*Routes of Administration: IV, PO | *Routes of Administration: IV, PO | ||
*Common Trade Names: | *Common Trade Names: Vfend | ||
==Adult Dosing== | ==Adult Dosing== | ||
| Line 29: | Line 29: | ||
*Renal failure | *Renal failure | ||
*Toxic encephalopathy | *Toxic encephalopathy | ||
*Pancreatitis | *[[Pancreatitis]] | ||
*Optic neuritis | *Optic neuritis | ||
===Common=== | ===Common=== | ||
| Line 46: | Line 46: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
* Triazole antifungal: inhibits synthesis of fungal cell wall ergosterol | *Triazole antifungal: inhibits synthesis of fungal cell wall ergosterol | ||
==Comments== | ==Comments== | ||
| Line 52: | Line 52: | ||
==See Also== | ==See Also== | ||
*[[Antifungals]] | *[[Antifungals]] | ||
*[[Fungal infections]] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:ID]] | |||
Latest revision as of 03:26, 8 March 2021
Administration
- Type: Antifungal (Candida, mycoses, Aspergillosis)
- Dosage Forms:
- Routes of Administration: IV, PO
- Common Trade Names: Vfend
Adult Dosing
- 200-400mg PO BID or 4-6mg IV BID
Pediatric Dosing
- Children >12 yo: same as adult dosing
Special Populations
- Pregnancy Rating: D
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: PO preferred, no adjustement to dose
- Hepatic dosing: mild-moderate impairment- reduce dose. Severe: avoid using
Contraindications
- Allergy to class/drug
- Concomitant use of carbamazepine or CYP3A4 substrates, ritonavir, ergots, barbiturates, rifampin, sirolimus, or St. John's Wort
Adverse Reactions
Serious
- Prolonged QT, dysrhythmias, cardiac arrest
- Erythema multiforme, SJS, TEN
- Malignant melanoma, squamous cell carcinoma
- Hepatotoxicity
- Renal failure
- Toxic encephalopathy
- Pancreatitis
- Optic neuritis
Common
- Peripheral edema
- Rash
- Nausea/vomiting, diarrhea
- Headache
- Visual disturbances
- Hallucinations
- Fever
Pharmacology
- Half-life: Dose dependant, non-linear pharmacokinetics
- Metabolism: CYP2C19, CYP2C9 and CYP3A4
- Excretion: Renal
Mechanism of Action
- Triazole antifungal: inhibits synthesis of fungal cell wall ergosterol